Because HSF1 is a pro-survival factor associated with resistance to treatment in multiple cancers (Dong et al, 2019, 2020), development of small-molecule inhibitors is providing the opportunity to test new combinatorial strategies to target resistant breast cancers. This evidence concerns the gene HSF1 and breast carcinoma.